checkAd
    Immuneering Registered (A) Aktie
    1,5700
     
    USD
    -1,88 %
    -0,0300 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,5600
     
    USD
    900 STK
    Geldkurs 15.05.24
    1,5700
     
    USD
    300 STK
    Briefkurs 15.05.24
    ISIN: US45254E1073 · WKN: A3CWDN · SYM: IMRX · USA

    Neueste Nachrichten

    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
    07.05.24 · globenewswire · Immuneering Registered (A)
    Immuneering Recognizes Melanoma Awareness Month
    06.05.24 · globenewswire · Immuneering Registered (A)
    IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
    09.04.24 · globenewswire · Immuneering Registered (A)
    Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    03.04.24 · globenewswire · Immuneering Registered (A)
    Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
    27.03.24 · globenewswire · Immuneering Registered (A)
    Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
    14.03.24 · globenewswire · Immuneering Registered (A)
    Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
    12.03.24 · globenewswire · Immuneering Registered (A)
    Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
    11.03.24 · globenewswire · Immuneering Registered (A)
    Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
    05.03.24 · globenewswire · Immuneering Registered (A)
    Immuneering to Participate in the Cowen 44th Annual Health Care Conference
    04.03.24 · globenewswire · Immuneering Registered (A)
    Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    01.03.24 · globenewswire · Immuneering Registered (A)
    Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
    20.02.24 · globenewswire · Immuneering Registered (A)